Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 9Lymphoma 4Leukemia 4Myelodysplastic Syndromes 3Lymphoma, Mantle-Cell 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Monocytic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Burkitt Lymphoma 2Blast Crisis 2Thrombocythemia, Essential 1Sezary Syndrome 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Polycythemia Vera 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 25Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × Cladribine × Clear all
NCT05330377 2023-04-25

GM-CLAG in Relapsed/Refractory FLT3-mutated AML

University of Kentucky

Phase 1 Withdrawn
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡